Lakhmir S. Chawla
Net Worth
Last updated:
What is Lakhmir S. Chawla net worth?
The estimated net worth of Dr. Lakhmir S. Chawla is at least $4,821,167 as of 30 Jan 2019. He owns shares worth $31,467 as insider and has received compensation worth at least $4,789,700 in La Jolla Pharmaceutical Company.
What is the salary of Lakhmir S. Chawla?
Dr. Lakhmir S. Chawla salary is $478,970 per year as Consultant in La Jolla Pharmaceutical Company.
How old is Lakhmir S. Chawla?
Dr. Lakhmir S. Chawla is 54 years old, born in 1971.
What stocks does Lakhmir S. Chawla currently own?
As insider, Dr. Lakhmir S. Chawla owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| La Jolla Pharmaceutical Company (LJPC) | Consultant | 5,059 | $6.22 | $31,467 |
What does La Jolla Pharmaceutical Company do?
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. As of August 22, 2022, La Jolla Pharmaceutical Company operates as a subsidiary of Innoviva, Inc.
Lakhmir S. Chawla insider trading
La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company key executives
La Jolla Pharmaceutical Company executives and other stock owners filed with the SEC:
- Dr. Lakhmir S. Chawla (54) Consultant
- Mr. Larry G. Edwards (53) Pres, Chief Executive Officer & Director
- Mr. Michael S. Hearne (62) Chief Financial Officer & Sec.